


**EXPRESS MAIL CERTIFICATE: EV667331102US**

I hereby certify that this correspondence listed below is being deposited with the United States Postal Service on the date set forth below as Express Mail in an envelope addressed to: Mail Stop PCT RO/US, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Signature  
and Deposit: May 19, 2006

By:   
(Signature of person depositing mail)  
MARITZA O'NEILL

**CERTIFICATE OF MAILING PURSUANT TO 37 C.F.R. 1.10**

Applicant(s)	:	Stephen P. Massia <i>et al.</i>
Serial No.	:	10/549,518
Date of Filing	:	September 14, 2005
Title	:	STABLE RGD PEPTIDOMIMETIC COMPOSITION
USPTO Customer No.	:	26707
Art Unit	:	To be assigned
Examiner	:	To be assigned
Attorney Docket No.	:	112624.00022

**Mail Stop: PCT RO/US**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Type of Filing:**

- 1) Copy of Notification to Comply dated 4/27/06;
- 2) Response to Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures (7 pages);
- 3) Statement Under 37 CFR 1.821(f) and 37 CFR 1.821(g);
- 4) Replacement Sheet for Fig. 4;
- 5) Paper copy of Sequence Listing (1 page);
- 6) Diskette with electronic copy of Sequence Listing; and
- 7) Return postcard.



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/549,518	Stephen P Massia	112624.00022

INTERNATIONAL APPLICATION NO.
-------------------------------

PCT/US04/11929

I.A. FILING DATE	PRIORITY DATE
------------------	---------------

04/16/2004

04/16/2003

26707  
 QUARLES & BRADY LLP  
 RENAISSANCE ONE  
 TWO NORTH CENTRAL AVENUE  
 PHOENIX, AZ 85004-2391

CONFIRMATION NO. 1335

371 FORMALITIES LETTER



\*OC000000018616705\*

Date Mailed: 04/27/2006

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application** and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

QBSL IP Dept.

Received on 5-2-06

Docket for OC: MKE

Taw

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/549,518	PCT/US04/11929	112624.00022

FORM PCT/DO/EO/922 (371 Formalities Notice)